Roche's New COVID-19 Point Of Care Test Scores FDA Emergency Use Nod

by Vandana Singh, Benzinga Editor
June 18, 2021 1:27 PM | 24 seconds read |
  • The FDA has granted Emergency Use Authorization (EUA) to Roche Holding AG's RHHBY Cobas SARS-CoV-2 Nucleic acid test for use on the Cobas Liat System.
  • This singleplex test is the first real-time RT-PCR test to identify SARS-CoV-2 infection within 20 minutes, both asymptomatic and symptomatic persons.
  • The test will be available in July.
  • Price Action: RHHBY shares down 0.75% at $47.14 during the market trading session on the last check Friday.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: BiotechNewsHealth CareFDAGeneralBriefsEmergency Use Authorization
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved